Dr. Reddy's Laboratories Ltd.
DRREDDYHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
5 transcript(s)/analyst meet(s) served; 1 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 5 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20211105 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220201 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220524 | 2022-03-31 | yes | |
| COVER_LETTER | 20220803 | 2022-06-30 | no | |
| TRANSCRIPT | 20221103 | 2022-09-30 | yes | |
| TRANSCRIPT | 20241111 | 2024-09-30 | yes | |
| TRANSCRIPT | 20251030 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260715 | 2026-06-30 | yes | |
| TRANSCRIPT | 20260728 | 2026-06-30 | yes |
DRREDDY
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 1,200.40 |
| 52-week range | 1135.6 – 1375.7 |
| Return 1M | 0.58% |
| Return 3M | -11.11% |
| Return 1Y | -7.53% |
| Return 3Y | 10.36% |
| Return 5Y | 25.29% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 8,100.00 |
| Other income | 355.00 |
| Total income | 8,454.00 |
| Cost of materials consumed | 1,654.00 |
| Purchases of stock-in-trade | 1,974.00 |
| Changes in inventories | -242.00 |
| Employee benefit expense | 1,652.00 |
| Finance costs | 126.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.27 | 0.00 |
| institutions foreign | 0.32 | -0.01 |
| institutions domestic | 0.32 | 0.01 |
| mutual funds | 0.13 | -0.00 |
| public | 0.73 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2022-06-30 | 1 |
| TRANSCRIPT | 2026-06-30 | 8 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 6,332.00 | 6,790.00 | 6,315.00 | 6,758.00 | 6,903.00 | 7,237.00 | 7,114.00 | 7,696.00 | 8,038.00 | 8,381.00 | 8,528.00 | 8,572.00 | 8,828.00 | 8,753.00 | 7,546.00 | 8,100.00 |
| Other income | 41.00 | 59.00 | 138.00 | 174.00 | 315.00 | 216.00 | 198.00 | 187.00 | 308.00 | 150.00 | 522.00 | 290.00 | 324.00 | 269.00 | 475.00 | 355.00 |
| Total income | 6,373.00 | 6,848.00 | 6,454.00 | 6,932.00 | 7,218.00 | 7,453.00 | 7,311.00 | 7,883.00 | 8,346.00 | 8,531.00 | 9,050.00 | 8,862.00 | 9,152.00 | 9,022.00 | 8,022.00 | 8,454.00 |
| Cost of materials consumed | 669.00 | 1,289.00 | 1,073.00 | 1,297.00 | 956.00 | 1,141.00 | 1,096.00 | 1,227.00 | 1,287.00 | 1,453.00 | 1,716.00 | 2,036.00 | 1,441.00 | 1,826.00 | 1,199.00 | 1,654.00 |
| Purchases of stock-in-trade | 809.00 | 916.00 | 767.00 | 877.00 | 1,138.00 | 1,208.00 | 1,176.00 | 1,380.00 | 1,283.00 | 1,051.00 | 1,128.00 | 1,216.00 | 1,746.00 | 1,542.00 | 1,658.00 | 1,974.00 |
| Changes in inventories | 369.00 | -204.00 | 59.00 | -236.00 | -91.00 | -174.00 | -180.00 | -426.00 | -203.00 | 78.00 | 6.00 | -444.00 | -64.00 | -272.00 | 356.00 | -242.00 |
| Employee benefit expense | 1,152.00 | 1,173.00 | 1,276.00 | 1,190.00 | 1,280.00 | 1,276.00 | 1,284.00 | 1,414.00 | 1,399.00 | 1,366.00 | 1,401.00 | 1,504.00 | 1,452.00 | 1,588.00 | 1,447.00 | 1,652.00 |
| Finance costs | 31.00 | 42.00 | 35.00 | 37.00 | 35.00 | 39.00 | 59.00 | 60.00 | 76.00 | 82.00 | 66.00 | 83.00 | 91.00 | 94.00 | 106.00 | 126.00 |
| Depreciation and amortisation | 309.00 | 324.00 | 316.00 | 353.00 | 376.00 | 374.00 | 368.00 | 381.00 | 397.00 | 471.00 | 455.00 | 476.00 | 505.00 | 521.00 | 557.00 | 537.00 |
| Other expenses | 1,434.00 | 1,677.00 | 1,607.00 | 1,568.00 | 1,611.00 | 1,761.00 | 1,907.00 | 1,971.00 | 2,196.00 | 2,160.00 | 2,280.00 | 2,088.00 | 2,243.00 | 2,182.00 | 2,504.00 | 2,203.00 |
| Total expenses | 4,773.00 | 5,217.00 | 5,132.00 | 5,086.00 | 5,305.00 | 5,627.00 | 5,710.00 | 6,007.00 | 6,434.00 | 6,661.00 | 7,051.00 | 6,958.00 | 7,414.00 | 7,481.00 | 7,827.00 | 7,902.00 |
| Profit before exceptional items and tax | 1,600.00 | 1,632.00 | 1,322.00 | 1,846.00 | 1,912.00 | 1,826.00 | 1,602.00 | 1,877.00 | 1,911.00 | 1,870.00 | 2,000.00 | 1,905.00 | 1,738.00 | 1,541.00 | 195.00 | 552.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1,600.00 | 1,632.00 | 1,322.00 | 1,846.00 | 1,912.00 | 1,826.00 | 1,602.00 | 1,877.00 | 1,911.00 | 1,870.00 | 2,000.00 | 1,905.00 | 1,738.00 | 1,541.00 | 195.00 | 552.00 |
| Current tax | 367.00 | 310.00 | 428.00 | 720.00 | 590.00 | 354.00 | 282.00 | 522.00 | 771.00 | 533.00 | 432.00 | 1,026.00 | 185.00 | 207.00 | -24.00 | 158.00 |
| Deferred tax | 132.00 | 84.00 | -59.00 | -275.00 | -156.00 | 94.00 | 13.00 | -31.00 | -196.00 | -63.00 | -14.00 | -531.00 | 223.00 | 146.00 | 2.00 | -40.00 |
| Tax expense | 499.00 | 394.00 | 369.00 | 445.00 | 434.00 | 448.00 | 295.00 | 490.00 | 576.00 | 470.00 | 418.00 | 495.00 | 408.00 | 354.00 | -22.00 | 118.00 |
| Profit for the period | 1,114.00 | 1,244.00 | 960.00 | 1,405.00 | 1,482.00 | 1,381.00 | 1,310.00 | 1,392.00 | 1,342.00 | 1,404.00 | 1,587.00 | 1,410.00 | 1,337.00 | 1,190.00 | 221.00 | 436.00 |
| Profit attributable to owners | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 1,256.00 | 1,414.00 | 1,593.00 | 1,418.00 | 1,347.00 | 1,210.00 | 221.00 | 444.00 |
| Profit attributable to non-controlling interests | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 86.00 | -10.00 | -7.00 | -8.00 | -10.00 | -20.00 | 0.00 | -9.00 |
| Other comprehensive income | -62.00 | 170.00 | 92.00 | 4.00 | -113.00 | 99.00 | -56.00 | 2.00 | 296.00 | -202.00 | 109.00 | 205.00 | 112.00 | 177.00 | 246.00 | 155.00 |
| Total comprehensive income | 1,052.00 | 1,414.00 | 1,053.00 | 1,409.00 | 1,369.00 | 1,480.00 | 1,254.00 | 1,394.00 | 1,638.00 | 1,202.00 | 1,696.00 | 1,615.00 | 1,449.00 | 1,367.00 | 467.00 | 591.00 |
| Earnings per share, basic | 67.13 | 74.91 | 57.79 | 84.55 | 89.09 | 82.94 | 78.66 | 83.61 | 15.08 | 16.97 | 19.12 | 17.04 | 16.18 | 14.53 | 2.65 | 5.33 |
| Earnings per share, diluted | 66.98 | 74.76 | 57.68 | 84.36 | 88.91 | 82.81 | 78.53 | 83.48 | 15.05 | 16.94 | 19.10 | 17.02 | 16.17 | 14.52 | 2.65 | 5.33 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 15,448.00 | 17,517.00 | 19,048.00 | 21,545.00 | 24,670.00 | 28,011.00 | 32,644.00 | 33,700.00 |
| Other income | 338.00 | 621.00 | 291.00 | 484.00 | 1,056.00 | 894.00 | 1,097.00 | 1,358.00 |
| Total income | 15,786.00 | 18,138.00 | 19,339.00 | 22,030.00 | 25,725.00 | 28,905.00 | 33,741.00 | 35,059.00 |
| Cost of materials consumed | 2,889.00 | 2,985.00 | 4,296.00 | 4,312.00 | 4,220.00 | 4,490.00 | 5,684.00 | 6,501.00 |
| Purchases of stock-in-trade | 1,881.00 | 2,546.00 | 2,574.00 | 3,484.00 | 3,367.00 | 4,399.00 | 4,841.00 | 6,162.00 |
| Changes in inventories | -275.00 | 24.00 | -790.00 | -354.00 | 71.00 | -680.00 | -545.00 | -424.00 |
| Employee benefit expense | 3,356.00 | 3,380.00 | 3,630.00 | 3,886.00 | 4,647.00 | 5,030.00 | 5,580.00 | 5,991.00 |
| Finance costs | 89.00 | 98.00 | 97.00 | 96.00 | 143.00 | 171.00 | 283.00 | 374.00 |
| Depreciation and amortisation | 1,135.00 | 1,163.00 | 1,229.00 | 1,165.00 | 1,250.00 | 1,470.00 | 1,704.00 | 2,059.00 |
| Other expenses | 4,419.00 | 6,112.00 | 5,469.00 | 6,450.00 | 6,016.00 | 6,839.00 | 8,537.00 | 9,017.00 |
| Total expenses | 13,494.00 | 16,308.00 | 16,503.00 | 19,038.00 | 19,714.00 | 21,719.00 | 26,083.00 | 29,679.00 |
| Profit before exceptional items and tax | 2,292.00 | 1,830.00 | 2,836.00 | 2,991.00 | 6,012.00 | 7,186.00 | 7,658.00 | 5,379.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 2,292.00 | 1,830.00 | 2,836.00 | 2,991.00 | 6,012.00 | 7,186.00 | 7,658.00 | 5,379.00 |
| Current tax | 471.00 | 662.00 | 817.00 | 1,101.00 | 814.00 | 1,946.00 | 2,258.00 | 1,394.00 |
| Deferred tax | -85.00 | -802.00 | 115.00 | -222.00 | 727.00 | -323.00 | -304.00 | -159.00 |
| Tax expense | 386.00 | -140.00 | 932.00 | 879.00 | 1,541.00 | 1,623.00 | 1,954.00 | 1,235.00 |
| Profit for the period | 1,950.00 | 2,026.00 | 1,952.00 | 2,182.00 | 4,507.00 | 5,578.00 | 5,725.00 | 4,158.00 |
| Profit attributable to owners | 1,950.00 | 2,026.00 | — | — | — | 0.00 | 5,655.00 | 4,196.00 |
| Profit attributable to non-controlling interests | 0.00 | — | — | — | — | 0.00 | 70.00 | -38.00 |
| Other comprehensive income | -109.00 | -65.00 | 540.00 | -290.00 | -12.00 | -66.00 | 205.00 | 740.00 |
| Total comprehensive income | 1,841.00 | 1,961.00 | 2,492.00 | 1,893.00 | 4,495.00 | 5,512.00 | 5,930.00 | 4,897.00 |
| Earnings per share, basic | 117.53 | 122.22 | 117.67 | 131.57 | 271.47 | 335.22 | 67.89 | 50.41 |
| Earnings per share, diluted | 117.33 | 121.99 | 117.34 | 131.21 | 270.90 | 334.59 | 67.79 | 50.35 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 29,169.00 | 32,285.00 | 34,809.00 | 38,864.00 | 46,728.00 | 49,427.00 | 54,373.00 | 58,123.00 |
| Non-current assets | 11,608.00 | 11,591.00 | 13,040.00 | 14,058.00 | 21,681.00 | 24,408.00 | 26,417.00 | 27,944.00 |
| Current assets | 17,561.00 | 20,694.00 | 21,770.00 | 24,805.00 | 25,048.00 | 25,018.00 | 27,956.00 | 30,179.00 |
| Property, plant and equipment | 5,167.00 | 5,654.00 | 5,850.00 | 6,249.00 | 6,726.00 | 7,298.00 | 9,119.00 | 10,078.00 |
| Capital work-in-progress | 1,161.00 | 975.00 | 1,151.00 | 1,351.00 | 1,852.00 | 2,399.00 | 1,997.00 | 1,460.00 |
| Goodwill | 522.00 | 547.00 | 541.00 | 550.00 | 1,316.00 | 1,314.00 | 1,404.00 | 1,480.00 |
| Other intangible assets | 3,104.00 | 3,018.00 | 3,638.00 | 3,627.00 | 9,143.00 | 9,614.00 | 10,094.00 | 10,506.00 |
| Inventories | 4,904.00 | 4,867.00 | 5,659.00 | 6,355.00 | 7,204.00 | 7,108.00 | 7,582.00 | 7,653.00 |
| Trade receivables | 7,699.00 | 7,248.00 | 6,972.00 | 8,030.00 | 8,440.00 | 9,042.00 | 9,775.00 | 10,123.00 |
| Cash and cash equivalents | 910.00 | 578.00 | 1,354.00 | 711.00 | 1,133.00 | 1,465.00 | 991.00 | 1,537.00 |
| Total equity and liabilities | 29,169.00 | 32,285.00 | 34,809.00 | 38,864.00 | 46,728.00 | 49,427.00 | 54,373.00 | 58,123.00 |
| Equity | 20,775.00 | 23,286.00 | 25,497.00 | 28,255.00 | 31,143.00 | 33,927.00 | 36,373.00 | 38,231.00 |
| Equity share capital | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 84.00 | 84.00 |
| Other equity | 20,692.00 | 23,203.00 | 25,413.00 | 28,171.00 | 30,666.00 | 33,466.00 | 35,930.00 | 37,808.00 |
| Total liabilities | 8,394.00 | 8,999.00 | 9,313.00 | 10,609.00 | 15,585.00 | 15,499.00 | 18,000.00 | 19,892.00 |
| Non-current liabilities | 407.00 | 427.00 | 906.00 | 1,021.00 | 2,664.00 | 2,465.00 | 2,896.00 | 3,145.00 |
| Current liabilities | 7,987.00 | 8,572.00 | 8,406.00 | 9,588.00 | 12,921.00 | 13,034.00 | 15,104.00 | 16,747.00 |
| Borrowings, non-current | 180.00 | 128.00 | 604.00 | 380.00 | 380.00 | 380.00 | 0.00 | 0.00 |
| Borrowings, current | 1,549.00 | 1,219.00 | 719.00 | 1,272.00 | 4,002.00 | 3,804.00 | 4,496.00 | 6,294.00 |
| Trade payables | 2,031.00 | 2,268.00 | 2,725.00 | 2,614.00 | 3,021.00 | 2,648.00 | 3,532.00 | 3,038.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 1,594.00 | 5,887.00 | 2,918.00 | 4,543.00 | 1,781.00 | 4,643.00 | 3,020.00 | 5,674.00 |
| Net cash from investing activities | 81.00 | -4,137.00 | -1,275.00 | -4,028.00 | -3,932.00 | -5,102.00 | -2,874.00 | -6,549.00 |
| Net cash from financing activities | -2,315.00 | -2,686.00 | -851.00 | -376.00 | 2,569.00 | 1,186.00 | -653.00 | 829.00 |
| Purchase of property, plant and equipment | 582.00 | 1,132.00 | 732.00 | 1,640.00 | 1,265.00 | 2,750.00 | 1,209.00 | 2,331.00 |
| Net increase in cash | -576.00 | -907.00 | 776.00 | 133.00 | 418.00 | 749.00 | -469.00 | 78.00 |
| con:CFO.BEFORE_TAX | 2,058.00 | 6,959.00 | 3,766.00 | 6,548.00 | 2,656.00 | 6,642.00 | 3,905.00 | 7,399.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -373.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 464.00 | 1,071.00 | 849.00 | 2,005.00 | 875.00 | 1,999.00 | 885.00 | 1,353.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 4,701.00 | 13,617.00 | 7,001.00 | 14,549.00 | 13,833.00 | 25,446.00 | 10,283.00 | 4,672.00 |
| con:INVESTMENTS_SOLD | 5,940.00 | 11,280.00 | 7,182.00 | 12,978.00 | 16,299.00 | 28,663.00 | 9,329.00 | 1,960.00 |
| con:PPE_DISPOSALS | 5.00 | 8.00 | 49.00 | 106.00 | 41.00 | 51.00 | 14.00 | 31.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 5,176.00 | 5,310.00 | 0.00 | 315.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 26.70 | 26.69 | 26.66 | 26.65 | 26.65 | 26.65 | 26.64 | 26.64 | 26.64 | 26.64 | 0.27 | 0.27 | 0.27 | 0.27 |
| Domestic institutions | 23.05 | 21.99 | 21.04 | 18.65 | 18.31 | 20.73 | 21.48 | 22.90 | 25.62 | 26.74 | 0.28 | 0.30 | 0.31 | 0.32 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 13.61 | 0.13 | 0.14 | 0.13 | 0.13 |
| Insurance companies | 12.99 | 12.56 | 10.14 | 7.94 | 7.72 | 7.88 | 7.70 | 8.96 | 10.00 | 10.58 | 0.12 | 0.14 | 0.15 | 0.15 |
| Foreign institutions | 38.55 | 39.54 | 42.21 | 43.96 | 44.49 | 42.27 | 41.75 | 40.08 | 37.29 | 36.36 | 0.36 | 0.33 | 0.33 | 0.32 |
| Public | 73.08 | 73.10 | 73.16 | 73.17 | 73.17 | 73.18 | 73.20 | 73.20 | 73.07 | 73.10 | 0.73 | 0.73 | 0.73 | 0.73 |
| Non-institutional | 11.48 | 11.57 | 9.91 | 10.57 | 10.38 | 10.19 | 9.97 | 10.22 | 10.15 | 10.00 | 0.10 | 0.09 | 0.09 | 0.09 |
| Shares outstanding | 147705687 | 145669793 | 143406930 | 141233798 | 141210209 | 142486414 | 143153651 | 724008985 | 738142936 | 742462506 | 744220502 | 743944550 | 735017457 | 739431524 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Dr. Reddy’s Laboratories Inc., USA | Holding-Subsidiary | Interest received, Purchase of goods or services, Sa | 65,436,750,000.00 | 7 |
| Dr. Reddy’s Laboratories SA, Switzerland | Holding-Subsidiary | Any other transaction, Interest received, Investment | 54,489,390,000.00 | 15 |
| Dr. Reddy's Nestle and Health Science Limited | Holding-Subsidiary | Any other transaction, Interest received, Investment | 16,439,160,000.00 | 7 |
| Dr. Reddy’s Laboratories LLC, Russia | Holding-Subsidiary | Purchase of goods or services, Sale of goods or serv | 11,743,750,000.00 | 3 |
| Aurigene Oncology Limited | Holding-Subsidiary | Investment | 6,500,000,000.00 | 1 |
| Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico | Holding-Subsidiary | Investment, Purchase of goods or services, Sale of g | 2,585,000,000.00 | 3 |
| Dr Reddy’s Laboratories LLP, Kazakhstan | Holding-Subsidiary | Purchase of goods or services, Sale of goods or serv | 1,832,000,000.00 | 2 |
| Dr. Reddy’s Laboratories (UK) Limited, UK | Holding-Subsidiary | Purchase of goods or services, Sale of goods or serv | 1,654,920,000.00 | 3 |
| Dr. Reddy’s Laboratories Romania SRL | Subsidiaries | Sale of goods or services | 1,331,610,000.00 | 2 |
| Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil | Holding-Subsidiary | Purchase of goods or services, Sale of goods or serv | 1,263,000,000.00 | 2 |
| Dr. Reddy’s Laboratories LLC, Ukraine | Holding-Subsidiary | Purchase of goods or services, Sale of goods or serv | 1,221,780,000.00 | 3 |
| Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa | Holding-Subsidiary | Sale of goods or services | 1,129,590,000.00 | 2 |
| betapharmArzneimittel GmbH, Germany | Holding-Subsidiary | Purchase of goods or services, Sale of goods or serv | 924,630,000.00 | 5 |
| Dr. Reddy's Venezuela, C.A. | Subsidiaries | Interest received, Loan | 908,000,000.00 | 2 |
| Dr. Reddy’s Laboratories Canada, Inc., Canada | Holding-Subsidiary | Any other transaction, Sale of goods or services | 867,100,000.00 | 4 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2022-11-03 | Q2FY23 | Read the call | |
| 2022-05-24 | Q4FY22 | Read the call | |
| 2022-02-01 | Q3FY22 | Read the call | |
| 2021-11-05 | Q2FY22 | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q2FY22 | Q2FY23 | Q3FY22 | Q4FY22 |
|---|---|---|---|---|
| Capex | — | Capital naturally first the basic use it for CAPEX, to use it for buying and building the future technologies and to use it for our working capital. | — | FTO-11 which is our coming up injectable facility that we are investing in it, actually quite a lot in the last couple of years will be one place of, … |
| Capital allocation | — | Adjusted for the covid product sales during Q2 FY'22, and the brand divestment income in Q1 of FY'23, we have grown in mid-teens year-over-year and mi… | — | Entered high-growth space of medical cannabis business in Germany through acquisition of Nimbus Health, 7. |
| Costs | My question is again on gross margins, in view of input material cost inflation, how should we look at trends in next few quarters? | And there is of course a little bit of cost inflation that is sitting in these numbers. | Just to understand, given we saw a double-digit price erosion in the US, but if you look at our generics' gross margins, they seem to have improved cl… | And then, one final question is for the US market, just now in one of the earnings calls concluded for one of your peers, this question was asked, I a… |
| Debt and cash | — | Number two, if I look at the cash flow statement for the business, there's roughly about Rs.600 crores that's been spent on intangibles. | — | Generation of strong free cash flow leading to a net surplus of more than $200 million, 6. |
| Demand | The overall normalizations of demand levels also contributed decent volumes across various categories of products impacted by COVID last year. | We have been progressing well in our journey of building a portfolio of complex and differentiated products, biosimilars and NCE pipeline. | However, the sales were impacted due to price erosion for some of our products as has been the case for the entire sector and seasonal demand variatio… | Additionally, we continue to focus on productivity, while simultaneously making investments to strengthen our pipeline and capabilities. |
| Guidance | We cannot specify or guiding any number there as per our policy. | While we wouldn't be able to mention specific sales volume or value arising from Lenalidomide, we expect this product to continue to contribute meanin… | We expect the performance to improve in the coming quarters. | We expect the launch momentum to further improve in FY23. Our Europe business recorded sales of €53 million this quarter with a strong year-on- year g… |
| Margin | It is encouraging that we are on track to deliver on our strategy while also delivering healthy EBITDA and ROCE. | And this is the main reason of lower gross margin. | The health of the business the way I dictate it is growth and EBITDA and ROCE. | EBITDA and ROCE in the range of our aspirational targets, 5. |
| Pricing | Sure and my last question is on US pricing scenario, so what kind of erosion we are facing right now and when do you expect it to normalize for the ba… | — | My second question would be a bit odd, but actually I wanted to understand on that part that whenever we launch the product, what is the average durat… | And if you can just broadly give the growth drivers in terms of pricing, volume and I think new products we are already aware, but would pricing be a … |
| Revenue growth | Our North America generic business recorded sales of $255 million for the quarter with a decent year-over-year growth of 3% and the sequential quarter… | Our North America Generics business recorded sales of $351 million for the quarter, with a strong growth of 38% year-over-year and 53% on a sequential… | Our North America generic business recorded sales of $248 million for the quarter with a year- on-year growth of 6% however a sequential quarter decli… | Our North America generics business recorded sales of $265 million for the quarter with a strong growth of 11% year-over-year and 7% on sequential bus… |